Why Rallybio Corporation’s (RLYB) Stock Is Up 19.92%
As of Monday, June 01, Rallybio Corporation’s RLYB share price has surged by 19.92%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Commentary & Analysis
Why Rallybio Corporation’s (RLYB) Stock Is Up 19.43%
As of Monday, June 01, Rallybio Corporation’s RLYB share price has surged by 19.43%, which has investors questioning if this is right time to sell.Omar Beirat
Why Rallybio Corporation’s (RLYB) Stock Is Down 5.41%
As of Thursday, March 12, Rallybio Corporation’s RLYB share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Rallybio Corporation’s (RLYB) Stock Is Down 5.02%
As of Tuesday, March 10, Rallybio Corporation’s RLYB share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Rallybio Corporation’s (RLYB) Stock Is Up 5.56%
As of Wednesday, March 04, Rallybio Corporation’s RLYB share price has surged by 5.56%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | RLYB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $89.6 | $289.2 | 20% |
|
| Shares Out (Mil) | 5.8 | 54.1 | 15% |
|
| Institutional Ownership | 67.0% | 93.1% | 41% |
|
| Float (Mil) | 2.2 | 42.2 | 6% |
|
| Beta | -0.86 | 0.94 | 1% |
|
| Avg Daily Volume (000s) | 9 | 451 | 17% |
|
| Price Change (52-week) |
265.3% | 59.8% | 98% |
|
| Growth | RLYB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 19.4% | (10.1%) | 72% |
|
| EPS (5yr) | 33.4% | 15.9% | 84 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (43.9%) | (15.6%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | na | |
| Current EPS | ($1.440) | ($5.520) | ($3.600) | |
| Month Ago EPS | ($1.440) | ($5.520) | na | |
| # Rev Up | na | 1 | 0 | |
| # Rev Down | na | 0 | 2 | |
| Three Months Ago EPS | ($1.440) | ($5.520) | na | |
| Year/Year Chg | (119.1%) | 246.1% | 95.6% | |
| Financials | RLYB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 1% |
|
| Net Income (TTM) (Mil) | $46 | ($43) | 54% |
|
| EPS (TTM) | $8.025 | ($1.500) | 92% |
|
| Operating Cash Flow (TTM) (Mil) | $27 | ($31) | 43% |
|
| Net Cash Flow (TTM) (Mil) | $83 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($5) | $190 | 2% |
|
| Valuation | RLYB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.95 | 2.84 | 20% |
|
| P/E | 2.1 | 20.4 | 2% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | 0.1 | 1.1 | 2% |
|
| Ratios | RLYB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | 61.1% | (47.8%) | 99% |
|
| ROE | 64.9% | (55.0%) | 94% |
|
| Liabilities to Assets | 3.6% | 29.7% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
Passing Stock Screens
As of 9/3/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 6.6% |
| +/- S&P 500: | -0.9 |
